154 related articles for article (PubMed ID: 37084616)
1. Generation of 2 isogenic clones from a patient with Trisomy 21 and a GATA1 mutation.
Takasaki K; Kumar SS; Gagne A; French DL; Chou ST
Stem Cell Res; 2023 Jun; 69():103098. PubMed ID: 37084616
[TBL] [Abstract][Full Text] [Related]
2. Generation of CHOPi-008-B, a euploid iPSC line from a patient with Trisomy 21 and a GATA1 mutation.
Takasaki K; Kumar SS; Gagne A; French DL; Chou ST
Stem Cell Res; 2023 Oct; 72():103198. PubMed ID: 37677872
[TBL] [Abstract][Full Text] [Related]
3. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
[TBL] [Abstract][Full Text] [Related]
4. Transient myeloproliferative disorder and GATA1 mutation in neonates with and without Down syndrome.
Tsai MH; Hou JW; Yang CP; Yang PH; Chu SM; Hsu JF; Chiang MC; Huang HR
Indian J Pediatr; 2011 Jul; 78(7):826-32. PubMed ID: 21287369
[TBL] [Abstract][Full Text] [Related]
5. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
[TBL] [Abstract][Full Text] [Related]
6. Synergistic roles of DYRK1A and GATA1 in trisomy 21 megakaryopoiesis.
Sit YT; Takasaki K; An HH; Xiao Y; Hurtz C; Gearhart PA; Zhang Z; Gadue P; French DL; Chou ST
JCI Insight; 2023 Oct; 8(23):. PubMed ID: 37906251
[TBL] [Abstract][Full Text] [Related]
7. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
[TBL] [Abstract][Full Text] [Related]
8. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
[TBL] [Abstract][Full Text] [Related]
9. Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model.
Arkoun B; Robert E; Boudia F; Mazzi S; Dufour V; Siret A; Mammasse Y; Aid Z; Vieira M; Imanci A; Aglave M; Cambot M; Petermann R; Souquere S; Rameau P; Catelain C; Diot R; Tachdjian G; Hermine O; Droin N; Debili N; Plo I; Malinge S; Soler E; Raslova H; Mercher T; Vainchenker W
J Clin Invest; 2022 Jul; 132(14):. PubMed ID: 35587378
[TBL] [Abstract][Full Text] [Related]
10. A neonate with a unique non-Down syndrome transient proliferative megakaryoblastic disease.
Bertrums EJ; Buijs A; van Grotel M; Dors N; de Rooij JD; de Haas V; Hopman S; Jongmans MC; Zwaan CM; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27667142
[TBL] [Abstract][Full Text] [Related]
11. Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome.
Alford KA; Slender A; Vanes L; Li Z; Fisher EM; Nizetic D; Orkin SH; Roberts I; Tybulewicz VL
Blood; 2010 Apr; 115(14):2928-37. PubMed ID: 20154221
[TBL] [Abstract][Full Text] [Related]
12. A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.
Haemmerling S; Behnisch W; Doerks T; Korbel JO; Bork P; Moog U; Hentze S; Grasshoff U; Bonin M; Rieß O; Janssen JW; Jauch A; Bartram CR; Reinhardt D; Koch KA; Bandapalli OR; Kulozik AE
Br J Haematol; 2012 Apr; 157(2):180-7. PubMed ID: 22296450
[TBL] [Abstract][Full Text] [Related]
13. Molecular insights into Down syndrome-associated leukemia.
Vyas P; Crispino JD
Curr Opin Pediatr; 2007 Feb; 19(1):9-14. PubMed ID: 17224656
[TBL] [Abstract][Full Text] [Related]
14. Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome.
Inaba H; Londero M; Maurer SH; Onciu M; Ge Y; Taub JW; Rubnitz JE; Raimondi SC
J Clin Oncol; 2011 Mar; 29(9):e230-3. PubMed ID: 21205752
[No Abstract] [Full Text] [Related]
15. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.
Carpenter E; Valverde-Garduno V; Sternberg A; Mitchell C; Roberts I; Vyas P; Vora A
Br J Haematol; 2005 Feb; 128(4):548-51. PubMed ID: 15686466
[TBL] [Abstract][Full Text] [Related]
16. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
Roy A; Roberts I; Norton A; Vyas P
Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
[TBL] [Abstract][Full Text] [Related]
17. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
[TBL] [Abstract][Full Text] [Related]
18. Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of
Barwe SP; Sebastian A; Sidhu I; Kolb EA; Gopalakrishnapillai A
Cells; 2022 Feb; 11(4):. PubMed ID: 35203280
[TBL] [Abstract][Full Text] [Related]
19. Natural history of GATA1 mutations in Down syndrome.
Ahmed M; Sternberg A; Hall G; Thomas A; Smith O; O'Marcaigh A; Wynn R; Stevens R; Addison M; King D; Stewart B; Gibson B; Roberts I; Vyas P
Blood; 2004 Apr; 103(7):2480-9. PubMed ID: 14656875
[TBL] [Abstract][Full Text] [Related]
20. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.
Malinge S; Bliss-Moreau M; Kirsammer G; Diebold L; Chlon T; Gurbuxani S; Crispino JD
J Clin Invest; 2012 Mar; 122(3):948-62. PubMed ID: 22354171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
